For: | Coppola M, Glinni D, Moreno M, Cioffi F, Silvestri E, Goglia F. Thyroid hormone analogues and derivatives: Actions in fatty liver. World J Hepatol 2014; 6(3): 114-129 [PMID: 24672641 DOI: 10.4254/wjh.v6.i3.114] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v6/i3/114.htm |
Number | Citing Articles |
1 |
Fernando Goglia. The effects of 3,5-diiodothyronine on energy balance. Frontiers in Physiology 2015; 5 doi: 10.3389/fphys.2014.00528
|
2 |
Ryo OMAGARI, Mayuko YAGISHITA, Miho YAMASAKI, Ryo KAMATA, Masanori TERASAKI, Fujio SHIRAISHI, Takuya KUBO, Daisuke NAKAJIMA. Evaluation of human thyroid receptor-agonist activity in 796 chemical compounds using a yeast two-hybrid assay with <i>Saccharomyces cerevisiae</i> Y190. Environmental Monitoring and Contaminants Research 2022; 2(0): 54 doi: 10.5985/emcr.20210016
|
3 |
|
4 |
Rosalba Senese, Pieter de Lange, Giuseppe Petito, Maria Moreno, Fernando Goglia, Antonia Lanni. 3,5-Diiodothyronine: A Novel Thyroid Hormone Metabolite and Potent Modulator of Energy Metabolism. Frontiers in Endocrinology 2018; 9 doi: 10.3389/fendo.2018.00427
|
5 |
Tomislav Kizivat, Ivana Maric, Dunja Mudri, Ines Bilic Curcic, Dragan Primorac, Martina Smolic. Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications. Journal of Clinical and Translational Hepatology 2020; 8(3): 1 doi: 10.14218/JCTH.2020.00027
|
6 |
Asma Bouazza, Roland Favier, Eric Fontaine, Xavier Leverve, Elhadj-Ahmed Koceir. Potential Applications of Thyroid Hormone Derivatives in Obesity and Type 2 Diabetes: Focus on 3,5-Diiodothyronine (3,5-T2) in Psammomys obesus (Fat Sand Rat) Model. Nutrients 2022; 14(15): 3044 doi: 10.3390/nu14153044
|
7 |
Maria Moreno, Antonia Giacco, Celia Di Munno, Fernando Goglia. Direct and rapid effects of 3,5-diiodo-L-thyronine (T2). Molecular and Cellular Endocrinology 2017; 458: 121 doi: 10.1016/j.mce.2017.02.012
|
8 |
|
9 |
Valeria Visco, Carmine Izzo, Davide Bonadies, Federica Di Feo, Giuseppe Caliendo, Francesco Loria, Costantino Mancusi, Pierpaolo Chivasso, Paola Di Pietro, Nicola Virtuoso, Albino Carrizzo, Carmine Vecchione, Michele Ciccarelli. Interventions to Address Cardiovascular Risk in Obese Patients: Many Hands Make Light Work. Journal of Cardiovascular Development and Disease 2023; 10(8): 327 doi: 10.3390/jcdd10080327
|
10 |
Luis A. Videla, Virginia Fernández, Pamela Cornejo, Romina Vargas, Iván Castillo. Thyroid hormone in the frontier of cell protection, survival and functional recovery. Expert Reviews in Molecular Medicine 2015; 17 doi: 10.1017/erm.2015.8
|
11 |
Arturo Hernandez. Thyroid Hormone and Alcoholic Fatty Liver: The Developmental Input. Alcoholism: Clinical and Experimental Research 2019; 43(9): 1834 doi: 10.1111/acer.14145
|
12 |
Bin Huang, Shengju Yang, Shandong Ye. Association between Thyroid Function and Nonalcoholic Fatty Liver Disease in Euthyroid Type 2 Diabetes Patients. Journal of Diabetes Research 2020; 2020: 1 doi: 10.1155/2020/6538208
|
13 |
Maik Pietzner, Beatrice Engelmann, Tim Kacprowski, Janine Golchert, Anna-Luise Dirk, Elke Hammer, K. Alexander Iwen, Matthias Nauck, Henri Wallaschofski, Dagmar Führer, Thomas F. Münte, Nele Friedrich, Uwe Völker, Georg Homuth, Georg Brabant. Plasma proteome and metabolome characterization of an experimental human thyrotoxicosis model. BMC Medicine 2017; 15(1) doi: 10.1186/s12916-016-0770-8
|
14 |
Roberta Imperatore, Lea Tunisi, Isabella Mavaro, Livia D’Angelo, Chiara Attanasio, Omid Safari, Hamidreza Ahmadniaye Motlagh, Paolo De Girolamo, Luigia Cristino, Ettore Varricchio, Marina Paolucci. Immunohistochemical Analysis of Intestinal and Central Nervous System Morphology in an Obese Animal Model (Danio rerio) Treated with 3,5-T2: A Possible Farm Management Practice?. Animals 2020; 10(7): 1131 doi: 10.3390/ani10071131
|
15 |
Claudia Mandato, Ida D’Acunzo, Pietro Vajro. Thyroid dysfunction and its role as a risk factor for non-alcoholic fatty liver disease: What’s new. Digestive and Liver Disease 2018; 50(11): 1163 doi: 10.1016/j.dld.2018.08.026
|
16 |
A. Baranova, D. Maltseva, A. Tonevitsky. Adipose may actively delay progression of NAFLD by releasing tumor‐suppressing, anti‐fibrotic miR‐122 into circulation. Obesity Reviews 2019; 20(1): 108 doi: 10.1111/obr.12765
|
17 |
Rui-Xu Yang, Jian-Gao Fan. Metabolic Steatotic Liver Disease. 2024; : 123 doi: 10.1016/B978-0-323-99649-5.00004-2
|
18 |
Xiaoxu Zeng, Bin Li, Yang Zou. The relationship between non-alcoholic fatty liver disease and hypothyroidism. Medicine 2021; 100(17): e25738 doi: 10.1097/MD.0000000000025738
|
19 |
Weiwei He, Xiaofei An, Ling Li, Xiaoqing Shao, Qian Li, Qiuming Yao, Jin-an Zhang. Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Frontiers in Endocrinology 2017; 8 doi: 10.3389/fendo.2017.00335
|
20 |
Riccardo Zucchi. Thyroid Hormone Analogues: An Update. Thyroid 2020; 30(8): 1099 doi: 10.1089/thy.2020.0071
|
21 |
Brijesh Kumar Singh, Rohit Anthony Sinha, Kenji Ohba, Paul Michael Yen. Role of thyroid hormone in hepatic gene regulation, chromatin remodeling, and autophagy. Molecular and Cellular Endocrinology 2017; 458: 160 doi: 10.1016/j.mce.2017.02.018
|
22 |
Rohit A. Sinha, Brijesh K. Singh, Paul M. Yen. Direct effects of thyroid hormones on hepatic lipid metabolism. Nature Reviews Endocrinology 2018; 14(5): 259 doi: 10.1038/nrendo.2018.10
|
23 |
Julika Lietzow, Janine Golchert, Maik Pietzner, Uwe Völker, Matti Poutanen, Claes Ohlsson, Georg Homuth, Josef Köhrle. Comparative Analysis of the Effects of Long-Term 3,5-diiodothyronine Treatment on the Murine Hepatic Proteome and Transcriptome Under Conditions of Normal Diet and High-Fat Diet. Thyroid 2021; 31(7): 1135 doi: 10.1089/thy.2020.0160
|
24 |
Serena Sagliocchi, Federica Restolfer, Alessandro Cossidente, Monica Dentice. The key roles of thyroid hormone in mitochondrial regulation, at interface of human health and disease. Journal of Basic and Clinical Physiology and Pharmacology 2024; 0(0) doi: 10.1515/jbcpp-2024-0108
|
25 |
|
26 |
Tomasz Charytoniuk, Krzysztof Drygalski, Karolina Konstantynowicz-Nowicka, Klaudia Berk, Adrian Chabowski. Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. Nutrition 2017; 34: 108 doi: 10.1016/j.nut.2016.09.001
|
27 |
Erifili Hatziagelaki, Stavroula A. Paschou, Martin Schön, Theodora Psaltopoulou, Michael Roden. NAFLD and thyroid function: pathophysiological and therapeutic considerations. Trends in Endocrinology & Metabolism 2022; 33(11): 755 doi: 10.1016/j.tem.2022.08.001
|
28 |
Sandra Incerpi, Paul J. Davis, Jens Z. Pedersen, Antonia Lanni. Principles of Endocrinology and Hormone Action. Endocrinology 2016; : 1 doi: 10.1007/978-3-319-27318-1_32-1
|
29 |
Ernest Yorke. Co-Morbid Hypothyroidism and Liver Dysfunction: A Review. Clinical Medicine Insights: Endocrinology and Diabetes 2024; 17 doi: 10.1177/11795514241231533
|
30 |
Janina Vaitkus, Jared Farrar, Francesco Celi. Thyroid Hormone Mediated Modulation of Energy Expenditure. International Journal of Molecular Sciences 2015; 16(7): 16158 doi: 10.3390/ijms160716158
|
31 |
Sandra Incerpi, Paul J. Davis, Jens Z. Pedersen, Antonia Lanni. Principles of Endocrinology and Hormone Action. Endocrinology 2018; : 259 doi: 10.1007/978-3-319-44675-2_32
|
32 |
Michail Kokkorakis, Chrysoula Boutari, Michael A. Hill, Vasilios Kotsis, Rohit Loomba, Arun J. Sanyal, Christos S. Mantzoros. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges. Metabolism 2024; 154: 155835 doi: 10.1016/j.metabol.2024.155835
|
33 |
Alessandro Federico, Claudio Zulli, Ilario de Sio, Anna Del Prete, Marcello Dallio, Mario Masarone, Carmela Loguercio. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World Journal of Gastroenterology 2014; 20(45): 16841-16857 doi: 10.3748/wjg.v20.i45.16841
|
34 |
Xin-Lu Ren, Peiyu Han, Yiteng Meng. Aflatoxin B1-Induced COX-2 Expression Promotes Mitophagy and Contributes to Lipid Accumulation in Hepatocytes In Vitro and In Vivo. International Journal of Toxicology 2020; 39(6): 594 doi: 10.1177/1091581820939081
|
35 |
Elena Silvestri, Maria Coppola, Federica Cioffi, Fernando Goglia. Proteomic approaches for the study of tissue specific effects of 3,5,3′-triiodo-L-thyronine and 3,5-diiodo-L-thyronine in conditions of altered energy metabolism. Frontiers in Physiology 2014; 5 doi: 10.3389/fphys.2014.00491
|
36 |
Eline H. van den Berg, Lynnda J.N. van Tienhoven-Wind, Marzyeh Amini, Tim C.M.A. Schreuder, Klaas Nico Faber, Hans Blokzijl, Robin P.F. Dullaart. Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the Lifelines Cohort Study. Metabolism 2017; 67: 62 doi: 10.1016/j.metabol.2016.11.002
|
37 |
Luigi Marino, Adam Kim, Bin Ni, Francesco S. Celi. Thyroid hormone action and liver disease, a complex interplay. Hepatology 2023; doi: 10.1097/HEP.0000000000000551
|
38 |
José de Jesús Garduño-Garcia, Eneida Camarillo Romero, Ana Loe Ochoa, Socorro Romero-Figueroa, Gerardo Huitron Bravo, Roció Torres García, Patricia Montenegro-Morales, Hugo Mendieta-Zerón. Thyroid function is associated with insulin resistance markers in healthy adolescents with risk factors to develop diabetes. Diabetology & Metabolic Syndrome 2015; 7(1) doi: 10.1186/s13098-015-0011-x
|
39 |
Julika Lietzow, Janine Golchert, Georg Homuth, Uwe Völker, Wenke Jonas, Josef Köhrle. 3,5-T2 alters murine genes relevant for xenobiotic, steroid, and thyroid hormone metabolism. Journal of Molecular Endocrinology 2016; 56(4): 311 doi: 10.1530/JME-15-0159
|
40 |
Livia López‐Noriega, Nadia Cobo‐Vuilleumier, Álvaro Jesús Narbona‐Pérez, Juan Luis Araujo‐Garrido, Petra Isabel Lorenzo, José Manuel Mellado‐Gil, José Carlos Moreno, Benoit R Gauthier, Alejandro Martín‐Montalvo. Levothyroxine enhances glucose clearance and blunts the onset of experimental type 1 diabetes mellitus in mice. British Journal of Pharmacology 2017; 174(21): 3795 doi: 10.1111/bph.13975
|